Prognosis of myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction: Risk stratification using cardiovascular magnetic resonance

Circulation: Cardiovascular Imaging

Volumn 9, Issue 1, 2016, Pages

  Murtagh, Gillian ^a   Laffin, Luke J ^a   Beshai, John F ^b   Maffessanti, Francesco ^a   Bonham, Catherine A ^a   Patel, Amit V ^a   Yu, Zoe ^a   Addetia, Karima ^a   Mor Avi, Victor ^a   Moss, Joshua D ^a   Hogarth, D Kyle ^a   Sweiss, Nadera J ^c   Lang, Roberto M ^a   Patel, Amit R ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Cardiac arrhythmias; Cardiac magnetic resonance; Cardiomyopathy; Defibrillator; Gadolinium; Heart failure; Sarcoidosis

Indexed keywords

GADOLINIUM; CONTRAST MEDIUM;

ADULT; AGED; ARTICLE; CARDIAC IMAGING; CARDIAC PATIENT; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONTRAST ENHANCEMENT; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE INJURY; HEART VENTRICLE FUNCTION; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SARCOIDOSIS; VERY ELDERLY; BIOPSY; CARDIOMYOPATHY; DISEASE COURSE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

BIOPSY; CARDIOMYOPATHIES; CONTRAST MEDIA; DISEASE PROGRESSION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SARCOIDOSIS; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 84955322179     PISSN: 19419651     EISSN: 19420080     Source Type: Journal    
DOI: 10.1161/CIRCIMAGING.115.003738     Document Type: Article

References (32)

1. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinico-pathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58:1204-1211.
2. Banba K, Kusano KF, Nakamura K, Morita H, Ogawa A, Ohtsuka F, Ogo KO, Nishii N, Watanabe A, Nagase S, Sakuragi S, Ohe T. Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis. Heart Rhythm. 2007;4:1292-1299. doi: 10.1016/j.hrthm.2007.06.006.
3. Viles-Gonzalez JF, Pastori L, Fischer A, Wisnivesky JP, Goldman MG, Mehta D. Supraventricular arrhythmias in patients with cardiac sarcoidosis prevalence, predictors, and clinical implications. Chest. 2013;143:1085-1090.
4. Cain MA, Metzl MD, Patel AR, Addetia K, Spencer KT, Sweiss NJ, Beshai JF. Cardiac sarcoidosis detected by late gadolinium enhancement and prevalence of atrial arrhythmias. Am J Cardiol. 2014;113:1556-1560. doi: 10.1016/j.amjcard.2014.01.434.
5. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA III, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Faxon DP, Halperin JL, Hiratzka LF, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura RA, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices); American Association for Thoracic Surgery; Society of Thoracic Surgeons. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/ NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;51:e1-62. doi: 10.1016/j.jacc.2008.02.032.
6. Schuller JL, Zipse M, Crawford T, Bogun F, Beshai J, Patel AR, Sweiss NJ, Nguyen DT, Aleong RG, Varosy PD, Weinberger HD, Sauer WH. Implantable cardioverter defbrillator therapy in patients with cardiac sarcoidosis. J Cardiovasc Electrophysiol. 2012;23:925-929. doi: 10.1111/j.1540-8167.2012.02350.x.
7. Kron J, Sauer W, Schuller J, Bogun F, Crawford T, Sarsam S, Rosenfeld L, Mitiku TY, Cooper JM, Mehta D, Greenspon AJ, Ortman M, Delurgio DB, Valadri R, Narasimhan C, Swapna N, Singh JP, Danik S, Markowitz SM, Almquist AK, Krahn AD, Wolfe LG, Feinstein S, Ellenbogen KA. Effcacy and safety of implantable cardiac defbrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis. Europace. 2013;15:347-354. doi: 10.1093/europace/eus316.
8. Freeman AM, Curran-Everett D, Weinberger HD, Fenster BE, Buckner JK, Gottschall EB, Sauer WH, Maier LA, Hamzeh NY. Predictors of cardiac sarcoidosis using commonly available cardiac studies. Am J Cardiol. 2013;112:280-285. doi: 10.1016/j.amjcard.2013.03.027.
9. Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, Meine TJ, White JB, Elliott MD, Kim HW, Judd RM, Kim RJ. Detection of myo-cardial damage in patients with sarcoidosis. Circulation. 2009;120:1969-1977. doi: 10.1161/CIRCULATIONAHA.109.851352.
10. Patel AR, Klein MR, Chandra S, Spencer KT, Decara JM, Lang RM, Burke MC, Garrity ER, Hogarth DK, Archer SL, Sweiss NJ, Beshai JF. Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: an observational study. Eur J Heart Fail. 2011;13:1231-1237. doi: 10.1093/eurjhf/hfr099.
11. Yazaki Y, Isobe M, Hiroe M, Morimoto S, Hiramitsu S, Nakano T, Izumi T, Sekiguchi M; Central Japan Heart Study Group. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88:1006-1010.
12. Chiu CZ, Nakatani S, Zhang G, Tachibana T, Ohmori F, Yamagishi M, Kitakaze M, Tomoike H, Miyatake K. Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol. 2005;95:143-146. doi: 10.1016/j. amjcard.2004.08.083.
13. Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, Judson MA, Kron J, Mehta D, Cosedis Nielsen J, Patel AR, Ohe T, Raatikainen P, Soejima K. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11:1305-1323. doi: 10.1016/j .hrthm.2014.03.043.
14. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after fve years' observation. Br Med J. 1961;2:1165-1172.
15. Crawford T, Mueller G, Sarsam S, Prasitdumrong H, Chaiyen N, Gu X, Schuller J, Kron J, Nour KA, Cheng A, Ji SY, Feinstein S, Gupta S, Ilg K, Sinno M, Abu-Hashish S, Al-Mallah M, Sauer WH, Ellenbogen K, Morady F, Bogun F. Magnetic resonance imaging for identifying patients with cardiac sarcoidosis and preserved or mildly reduced left ventricular function at risk of ventricular arrhythmias. Circ Arrhythm Electrophysiol. 2014;7:1109-1115. doi: 10.1161/CIRCEP.113.000156.
16. Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Dassen WR, Gorgels AP, Crijns HJ. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45:1683-1690. doi: 10.1016/j. jacc.2005.01.047.
17. Greulich S, Deluigi CC, Gloekler S, Wahl A, Zürn C, Kramer U, Nothnagel D, Bültel H, Schumm J, Grün S, Ong P, Wagner A, Schneider S, Nassenstein K, Gawaz M, Sechtem U, Bruder O, Mahrholdt H. CMR imaging predicts death and other adverse events in suspected cardiac sar-coidosis. JACC Cardiovasc Imaging. 2013;6:501-511. doi: 10.1016/j.jcmg.2012.10.021.
18. Roberts WC, McAllister HA Jr, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med. 1977;63:86-108.
19. Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med. 1995;119:167-172.
20. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML; Multicenter Automatic Defbrillator Implantation Trial II Investigators. Prophylactic implantation of a defbrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883. doi: 10.1056/ NEJMoa013474.
21. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Sanders WE, Schaechter A, Levine JH; Defbrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defbrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151-2158. doi: 10.1056/NEJMoa033088.
22. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defbrillator for congestive heart failure. N Engl J Med. 2005;352:225-237. doi: 10.1056/ NEJMoa043399.
23. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, Bundy J, Finn JP, Klocke FJ, Judd RM. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100:1992-2002.
24. Wagner A, Mahrholdt H, Holly TA, Elliott MD, Regenfus M, Parker M, Klocke FJ, Bonow RO, Kim RJ, Judd RM. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet. 2003;361:374-379. doi: 10.1016/S0140-6736(03)12389-6.
25. Tadamura E, Yamamuro M, Kubo S, Kanao S, Saga T, Harada M, Ohba M, Hosokawa R, Kimura T, Kita T, Togashi K. Effectiveness of delayed enhanced MRI for identifcation of cardiac sarcoidosis: comparison with radionuclide imaging. AJR Am J Roentgenol. 2005;185:110-115. doi: 10.2214/ajr.185.1.01850110.
26. Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Cheriex EC, Gorgels AP, Crijns HJ. The additional value of gadolinium-enhanced MRI to standard assessment for cardiac involvement in patients with pulmonary sarcoidosis. Chest. 2005;128:1629-1637. doi: 10.1378/chest.128.3.1629.
27. Nagai T, Kohsaka S, Okuda S, Anzai T, Asano K, Fukuda K. Incidence and prognostic signifcance of myocardial late gadolinium enhancement in patients with sarcoidosis without cardiac manifestation. Chest. 2014;146:1064-1072. doi: 10.1378/chest.14-0139.
28. Mehta D, Mori N, Goldbarg SH, Lubitz S, Wisnivesky JP, Teirstein A. Primary prevention of sudden cardiac death in silent cardiac sarcoidosis: role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol. 2011;4:43-48. doi: 10.1161/CIRCEP.110.958322.
29. Crouser ED, Ono C, Tran T, He X, Raman SV. Improved detection of cardiac sarcoidosis using magnetic resonance with myocardial T2 mapping. Am J Respir Crit Care Med. 2014;189:109-112. doi: 10.1164/ rccm.201309-1668LE.
30. 18F-fuorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol. 2014;21:166-174. doi: 10.1007/s12350-013-9828-6.
31. Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, Kazemian P, Kwong RY, Tokuda M, Skali H, Padera R, Hainer J, Stevenson WG, Dorbala S, Di Carli MF. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63:329-336. doi: 10.1016/j. jacc.2013.09.022.
32. Tukey MH, Berman JS, Boggs DA, White LF, Rosenberg L, Cozier YC. Mortality among African American women with sarcoidosis: Data from the Black Women's Health Study. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30:128-133.